Literature DB >> 11418009

Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.

E B Claus1, P Chu, C L Howe, T L Davison, D F Stern, D Carter, M P DiGiovanna.   

Abstract

With the increasing incidence of ductal carcinoma in situ (DCIS) of the breast and its relationship to invasive breast carcinoma, it is important to understand the biology of this entity. We report on a hospital-based survey of 219 case subjects with DCIS of the breast without associated invasive carcinoma diagnosed between 1982 and 1994. The cases of DCIS were analyzed for architectural type, size, nuclear grade, necrosis, calcification, periductal fibrosis, neovascularization, estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu expression. Periductal neovascularization was associated with tumor size, microcalcifications, periductal fibrosis, and HER-2/neu overexpression. Expression of ER and PR was observed in 60 and 62% of the cases, respectively, and HER-2/neu overexpression in 28% of the cases. ER and PR expression were both inversely associated with comedo histology and nuclear grade. HER-2/neu overexpression was positively associated with comedo histology, high nuclear grade, and periductal neovascularization and was inversely correlated with both ER and PR expression. High nuclear grade was positively associated with comedocarcinoma, necrosis, microcalcification, and periductal fibrosis. The role of these molecular/pathologic markers in the biology of DCIS and their potential clinical implications are discussed. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418009     DOI: 10.1006/exmp.2001.2366

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  24 in total

1.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Authors:  Kalliopi P Siziopikou; Stewart J Anderson; Melody A Cobleigh; Thomas B Julian; Douglas W Arthur; Ping Zheng; Eleftherios P Mamounas; Eduardo R Pajon; Robert J Behrens; Janice F Eakle; Nick C Leasure; James N Atkins; Jonathan A Polikoff; Thomas E Seay; Worta J McCaskill-Stevens; Rachel Rabinovitch; Joseph P Costantino; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2013-11-08       Impact factor: 4.872

2.  Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions.

Authors:  Nuiki Iota Chantzi; Marina Palaiologou; Artemis Stylianidou; Nikos Goutas; Stamatis Vassilaros; Helen P Kourea; Eugen Dhimolea; Dimitra J Mitsiou; Dina G Tiniakos; Muichael N Alexis
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-27       Impact factor: 4.553

3.  Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.

Authors:  Yanli Yan; Long Zhang; Li Tan; Xiaowei Ma; Yong Zhang; Shuai Shao; Jiaxin Liu; Chaofan Xue; Zongfang Li; Xiaozhi Zhang; Emmanuel Kwateng Drokow; Xiaoting Shi; Juan Ren
Journal:  Pathol Oncol Res       Date:  2018-11-29       Impact factor: 3.201

Review 4.  Ductal Carcinoma In Situ: Treatment Update and Current Trends.

Authors:  Katrina B Mitchell; Henry Kuerer
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

Review 5.  What is the malignant nature of human ductal carcinoma in situ?

Authors:  Virginia Espina; Lance A Liotta
Journal:  Nat Rev Cancer       Date:  2010-12-02       Impact factor: 60.716

6.  Computer-aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in situ: Correlating histologic grade and receptor status.

Authors:  Shinn-Huey S Chou; Eva C Gombos; Sona A Chikarmane; Catherine S Giess; Jagadeesan Jayender
Journal:  J Magn Reson Imaging       Date:  2017-04-03       Impact factor: 4.813

7.  Attacking breast cancer at the preinvasion stage by targeting autophagy.

Authors:  Virginia Espina; John Wysolmerski; Kirsten Edmiston; Lance A Liotta
Journal:  Womens Health (Lond)       Date:  2013-03

Review 8.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

9.  Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Authors:  Gaiane M Rauch; Henry M Kuerer; Marion E Scoggins; Patricia S Fox; Ana P Benveniste; Young Mi Park; Sara A Lari; Brian P Hobbs; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang
Journal:  Breast Cancer Res Treat       Date:  2013-06-18       Impact factor: 4.872

Review 10.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.